Press Release Library
DateTitle
September 2011Prolia®▼ (denosumab) phase 2 extension study showed continued increase in bone mineral density over eight years of treatment
July 2011Xgeva®▼ (denosumab) granted marketing authorisation in the European Union
June 2011Phase 3 data demonstrate denosumab is first Bone targeted therapy to prevent spread of Cancer to the bone in men with advanced Prostate cancer
April 2011The Journal of Clinical Oncology publishes phase 3 Denosumab results in advanced cancer patients with solid tumours or Multiple Myeloma
April 2011Results published in the Lancet demonstrate superiority of Denosumab in the prevention of bone complications for me with bone metastases from advanced prostate cancer
March 2011Prolia®▼(Denosumab) open-label extension trial showed continued increase in bone mineral density over five years of treatment with similar safety profile observed in pivotal trial
March 2011Treatment with Prolia®▼(Denosumab) associated with sigificantly greater adherence, compliance and persistance compared to Aledronate
December 2010Scottish Medicines Consortium recommends Prolia® ▼ (denosumab) for the treatment of postmenopausal osteoporosis
November 2010Published results show Denosumab superior to Zometa® in delaying or preventing bone complications in patients with bone metastases from advanced breast cancer
October 2010NICE issues final recommendation for Prolia® (denosumab) for the treatment of post-menopausal osteoporosis
October 2010Is the UK Reaching Breaking Point?
June 2010New analyses of Denosumab Pivotal phase 3 trials reinforec potential advantages over standard of care
June 2010Denosumab demonstrated superiorority over Zometa in delay of complications due to bone metasases in advanced prostate cancer.
June 2010New data confirms the negative impact of febrile neutropenia in patients with non-hodgkin lymphoma receiving
May 2010Amgen highlights key clinical data to be presented at American Society of Clicnical Oncology annual meeting
April 2010Chemotherapy-Induced Neutropenia Can Cause Additional Burden and Risk for Cancer Patients, Pan-European